- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Good
|
- 10-K Annual report
- 2.2 Amendment No. 1 to Separation and Distribution Agreement
- 10.26 Amendment No. 2 to Patent Licensing Master Agreement
- 10.28 Patent License Agreement - Medimmune Inc.
- 10.29 Patent License Agreement - Elan International Services LTD.
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 Certification of Peo Pursuant to Rule 13A-14(A) or Rule 15D-14(A)
- 31.2 Certification of Pfo Pursuant to Rule 13A-14(A) or Rule 15D-14(A)
- 32.1 Certification by the Peo and the Pfo
Exhibit 32.1
CERTIFICATION
John P. McLaughlin, President and Chief Executive Officer, and Christine Larson, Vice President and Chief Financial Officer, of PDL BioPharma, Inc. (the “Registrant”), each hereby certifies in accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, based on his or her knowledge:
(1) The Annual Report on Form 10-K for the fiscal year ended December 31, 2008 of the Registrant, to which this certification is attached as an exhibit (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
A signed original of this written statement required by Section 906 will be provided to the Securities and Exchange Commission or its staff upon request.
Dated: March 2, 2009
By: |
/s/ John P. McLaughlin John P. McLaughlin President and Chief Executive Officer (Principal Executive Officer) |
/s/ Christine Larson Christine Larson Vice President and Chief Financial Officer (Principal Financial Officer) |